Business Context and Reporting Period
Company: Oxygen Biotherapeutics, Inc. (formerly Synthetic Blood International, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 31, 2009
Business Overview: A development-stage biotechnology company focused on oxygen delivery products. Key assets include Oxycyte (oxygen carrier for surgical use), Vitavent/Fluorovent (medical devices for lung conditions), and Dermacyte (topical cosmetic line). The company has no commercial revenue from its primary pharmaceutical products and relies on financing to fund clinical trials and regulatory approvals.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 2009 | Six Months Ended Oct 31, 2009 | Balance Sheet (Oct 31, 2009) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,589,212) | $(4,985,890) | Accumulated Deficit: $(75,946,092) |
| Operating Expenses | $2,593,051 | $4,883,586 | N/A |
| Interest Expense | $23,274 | $150,699 | N/A |
| Cash and Equivalents | N/A | N/A | $975,024 |
| Working Capital | N/A | N/A | $5,315,980 |
| Total Liabilities | N/A | N/A | $1,651,773 |
| Stockholders' Equity | N/A | N/A | $6,589,576 |
Note: The company reported no revenue. Operating expenses were driven by Research & Development ($407k for Q3; $946k for 6 months) and General & Administrative costs ($2.19M for Q3; $3.94M for 6 months).
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $1.32 million for the three months and $3.18 million for the six months compared to the prior year periods. This improvement was primarily due to a significant decrease in interest expense (down ~$1.6M and ~$2.7M respectively) resulting from the conversion of convertible notes to equity.
- Expense Composition: While total operating expenses decreased slightly year-over-year for the six-month period, the composition shifted. R&D expenses increased due to Dermacyte formulation costs and pre-clinical studies. G&A expenses decreased due to the absence of ~$1M in CEO option compensation costs incurred in the prior year, though payroll costs rose due to headcount expansion (from 6 to 21 employees).
- Liquidity Position: Cash and cash equivalents decreased from $2,555,872 at April 30, 2009, to $975,024 at October 31, 2009. However, the company recorded a significant "Other receivable" of $5,422,813 related to a milestone financing agreement.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Financing Milestones: The company entered a Securities Purchase Agreement with the Vatea Fund. A milestone was triggered in August 2009 (Swissmedic approval for Phase II trials), obligating the fund to purchase an additional 1.6 million shares for $6 million. As of the filing date, $531,000 had been received, with the remainder expected by December 10, 2009.
- Product Development: Phase II clinical trials for Oxycyte began in October 2009 in Switzerland. The company launched its first commercial product, Dermacyte, in November 2009, though this is considered a speculative venture.
- Capital Runway: Management believes current working capital ($5.3M) plus expected milestone funding is sufficient to fund operations through the second quarter of fiscal year 2011.
Risks and Contingencies
- Going Concern: The company has an accumulated deficit of $75.9 million and sustained operating losses. The financial statements include a "substantial doubt" disclosure regarding the company's ability to continue as a going concern, dependent on future financing and product success.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of October 31, 2009, due to material weaknesses in the control environment, including inconsistent maintenance of contracts and insufficient accounting staff knowledge. Remediation efforts are underway.
- Regulatory Risk: Success depends on FDA and foreign regulatory approvals. Previous clinical holds on Oxycyte highlight the risks of the development process.
Investor Verification Checklist
- Milestone Funding Closure: Verify the receipt of the remaining $5.479 million from the Vatea Fund milestone payment, which was recorded as a receivable but not yet fully collected as of October 31, 2009.
- Reverse Stock Split: Confirm the impact of the 1-for-15 reverse stock split effective November 9, 2009, on share count and per-share metrics (post-split shares trade under symbol OXBT).
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting, specifically regarding contract management and accounting staff competency.
- Cash Burn Rate: Assess whether the $975k cash on hand (excluding the receivable) is sufficient to cover immediate operational costs if the milestone funding is delayed.
- Dermacyte Sales: Verify actual sales figures for the newly launched Dermacyte product line, as the company currently has no revenue from its core pharmaceutical pipeline.